Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Raymond James Initiates Coverage On Taysha Gene Therapies with Strong Buy Rating, Announces Price Target of $13

Author: Benzinga Newsdesk | October 21, 2025 12:43pm
Raymond James analyst Christopher Raymond initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Strong Buy rating and announces Price Target of $13.

Posted In: TSHA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist